Seeking Alpha
View as an RSS Feed

Biomed Group  

View Biomed Group's Comments BY TICKER:
Latest comments  |  Highest rated
  • EnteroMedics: Recent Sell-Off In Biotech Creates A Great Entry Opportunity [View article]
    The safety and efficacy shown by the device in clinical trials should be sufficient to gain FDA approval. The company benefits from the lack of options available for the obese patient population, risks associated with current options, and long-term risks/costs of obesity in general due to co-morbidities. As Biotech Dan pointed out, sales are a non-issue at this point, but might be an issue in the future.
    Apr 16, 2014. 05:31 PM | Likes Like |Link to Comment
  • EnteroMedics: Recent Sell-Off In Biotech Creates A Great Entry Opportunity [View article]
    Nice answer, Biotech Dan.
    Apr 16, 2014. 04:45 AM | Likes Like |Link to Comment
  • Omeros Corporation's Stock Has Potential To Double This Year [View article]
    We sold the stock at around $13 in October, 2013 for an average share price gain of 135%. However, we don't see the current level as attractive.
    Mar 17, 2014. 12:23 PM | Likes Like |Link to Comment
  • Chimerix: A Significant Player In The Antiviral Therapeutics Market [View article]
    CMRX is up 31% since we evaluated it on Nov. 26, 2013.
    Mar 2, 2014. 05:54 PM | Likes Like |Link to Comment
  • Fibrocell Science: An Attractive Healthcare Investment [View article]
    The stock is up 42% since we evaluated it on Jan. 1, 2014.
    Mar 2, 2014. 05:50 PM | Likes Like |Link to Comment
  • Five Prime: A Growing Oncology And Inflammatory Player With A Promising Pipeline [View article]
    The stock is up 44% since we evaluated it on Oct. 30, 2013. There is still more room to the upside.
    Jan 14, 2014. 06:36 PM | 1 Like Like |Link to Comment
  • Five Prime: A Growing Oncology And Inflammatory Player With A Promising Pipeline [View article]
    Now 20% higher.
    Dec 16, 2013. 08:49 AM | Likes Like |Link to Comment
  • Onyx Pharmaceuticals: Kyprolis Is The Key Driver Of Future Growth [View article]
    We appreciate your comment, apologize, and assure you it won't happen again in the future. Moreover, you right, we know nothing about effective marketing. However, we do have some knowledge in Biomed :) Take care and all the best!
    Mar 21, 2013. 01:40 PM | Likes Like |Link to Comment
  • Medivation: Early Launch Of Xtandi Appears Solid [View article]
    Publicity and fun.
    Mar 6, 2013. 11:20 AM | Likes Like |Link to Comment
  • Omeros Corporation's Stock Has Potential To Double This Year [View article]
    We think the ATM with MLV & Co was established as insurance and as potential leverage in partnering discussions. As we mentioned in the article, the CEO pointed out that the company is now in partnering discussions to all or almost all of its programs. With that said, we believe that any dip in OMER is a real opportunity. Take care.
    Feb 19, 2013. 06:06 PM | 1 Like Like |Link to Comment
  • Omeros Corporation's Stock Has Potential To Double This Year [View article]
    Hi Vaffan. We appreciate your opinion. However, you are overreacting and misleading. As such, the company’s insurer, Carolina Casualty, has agreed to make the full payment of the 4 million you mentioned. Moreover, the company has none-dilutive financing options as potential partnerships for their various drug candidates as well as the GPCR program. The company also has $40 million of equity credit line which it had not used. And last, the analyst firms we mentioned are well respected in the biotechnology industry. Wedbush ranked top stock picking firm for 2012. Take care.
    Feb 19, 2013. 11:22 AM | 1 Like Like |Link to Comment
  • Amgen: A Long-Term Growth Story [View article]
    Thanks Mark. Jefferies currently has one year price target of $100 on AMGN.
    Feb 12, 2013. 09:55 PM | Likes Like |Link to Comment
  • Amgen: A Long-Term Growth Story [View article]
    Thanks!
    Feb 11, 2013. 04:06 PM | Likes Like |Link to Comment
COMMENTS STATS
13 Comments
3 Likes